Weekly Recap | Gilead Sciences -4.82%, most brokers rate it buyWeekly Review·Sep 12 at 08:16 AMGILD+0.14%
Weekly Recap | Gilead Sciences +3.65%, FDA approves new HIV tabletWeekly Review·Sep 5 at 07:02 AMGILD+0.14%
Weekly Recap | Gilead Sciences -0.3%, FDA approves once-daily HIV pillWeekly Review·Aug 29 at 05:38 AMGILD+0.14%
